Showing 1–25 of 47 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Caterina Davoli, Chiara Rossi, Andrea Ciccarone, Francesca Bertoni, Marina Calamelli, et al.
…t and breastfeeding women. A key difference between the two regimens is the replacement of pretomanid with delamanid in the BDLLfxC. However, limitations remain. Neither BPaLM nor BDLLfxC are recommended in patients with complicated forms of extrapulmonary MDR-TB: central nervous…
Rosella Centis, Lia D'Ambrosio, Giovanni Battista Migliori
…rne infectious disease treated with combination therapeutic regimens. Adherence to long-term antituberculosis therapy is crucial to maintain adequate blood drug level. The emergence and spread of drug-resistantstrains is mainly favored by the inadequate medical management of pati…
M Amiri, M Cheraghi, M J Nasiri, D R Silva, G Sotgiu, et al.
…revious review summarised the evolution and efficacy of the regimens to treat rifampicin-resistant/multidrug-resistant TB (RR/MDR-TB), underscoring the persistent need for efficacious shorter treatments. The aim of this scoping review was to explore safety, quality of life (QoL),…
Miriam Abadie, Alexander Kay
…ed therapy, as well as emerging evidence on novel treatment regimens, post-TB complications, and DR-TB medication resistance among PWH. **RECENT FINDINGS:** Treatment for DR-TB has evolved to shorter, all-oral regimens with reduced drug-drug interactions. However, emerging dolut…
Aneeka Chavda, Mark Gilchrist, Toby Capstick, Christabelle Chen, Onn Min Kon
…at associated with high mortality and challenging treatment regimens. The UK, like many countries, faces a growing incidence of MDR-TB, with 105 (1.9% of all notified cases) treated as MDR-resistant or rifampicin-resistant TB in 2024. Recent clinical trials have demonstrated the …
Gail B Cross
…ew therapeutics, repurposed agents, and shortened treatment regimens. It aims to contextualize key developments within the evolving TB treatment landscape and assess their potential to transform clinical management of both drug-susceptible and drug-resistant disease. **RECENT FI…
Chiara Sepulcri, Francesca Saluzzo, Daniele Roberto Giacobbe, Antonio Di Biagio, Daniela Maria Cirillo, et al.
…therapeutic advances. The shift from long, injectable-based regimens to shorter, all-oral regimens has improved outcomes, yet substantial challenges remain in ensuring efficacy, safety, and equitable access. **AREAS COVERED:** We reviewed recent literature (2020-2025) searching …
Vidya Mave, Mandar Paradkar, Francesca Conradie, Amita Gupta, Anchalee Avihingsanon, et al.
Over the past 80 years, tuberculosis treatment has evolved with the development of all-oral treatments, which are now given for 4-6 months for drug-sensitive tuberculosis and 6-9 months for drug-resistant tuberculosis. Treatment success is often reduced among people with HIV due …
Edine Tiemersma, Susan van den Hof, Michael Kimerling
In 2014, with new drugs and regimens becoming available for the treatment of multidrug-resistant (MDR) tuberculosis (TB), the World Health Organization (WHO) recommended that countries should conduct active pharmacovigilance (PV) for these new drugs and regimens. Because of the c…
Jin Li, Yanmei Wang, Lei He, Luchuan Yang, Tao Tao, et al.
Although current combination regimens of antibiotics have significantly improved tuberculosis (TB) cure rates, substantial challenges persist in the global effort to end TB. These include poor patient compliance, the emergence of drug-resistant strains due to prolonged treatments…
Rafael Laniado-Laborín
One-third of the world's population is infected with M. tuberculosis. It is from this vast pool of infected people where the new cases of active disease originate. Most of these cases of latent infection are found in low-income countries where national tuberculosis programs conce…
Christian Tague
…ntituberculosis drugs, as well as the toxicity of prolonged regimens, further complicate clinical management. Mortality among coinfected patients remains high, sometimes exceeding 40%, particularly in the absence of early diagnosis and adequate treatment. Improved early detection…
Marcos Abdo Arbex
Tuberculosis (TB) remains a critical global public health challenge, requiring therapeutic strategies that ensure high cure rates while minimizing bacillary transmission. The 2022 World Health Organization (WHO) update for drug-resistant TB treatment prioritized a novel, 6-month,…
Ravindra Kumar Garg
…rospinal fluid (CSF) tests. Standard pulmonary tuberculosis regimens are suboptimal for central nervous system involvement due to poor drug penetration and prolonged treatment. Emerging resistance, particularly to rifampicin and isoniazid, further complicates the management. **A…
María Asunción Pérez-Jacoiste Asín, Francisco López-Medrano, José María Aguado
…ften undergo more intensive and prolonged immunosuppressive regimens compared to recipients of other organ transplants with lower immunogenicity. Additionally, the risk of donor-derived TB is notably higher in lung transplantation, underscoring the critical importance of thorough…
H Manisha Yapa, Emily L-H MacLean, Nicolas A Menzies, Peter J Dodd, Anna Dean, et al.
…chronic lung disease, impacting quality of life. Newer oral regimens for multidrug-resistant TB are shorter and more effective than traditional regimens. New antibiotics under development may help overcome remaining safety and tolerability issues, while novel advanced therapeutic…
Sandeep Rai, Abhishek Sen, Harsh Shah, Jay Patel
…nel, inadequate referral chains, and inconsistent treatment regimens. Lack of streamlined referral pathways and non-standardised treatment regimens posed problematic operational challenges. Weak involvement from the private sector and lack of training and supervision of frontline…
Ashish Kumar Prakash, Chinkita Agrawal, Nishant Gupta, Pinky Goyal, Anand Jaiswal
**BACKGROUND:** Therapeutic Drug Monitoring (TDM) helps in optimizing the dose which maximizes the therapeutic benefit and minimizes the toxicity. In pulmonary and extrapulmonary tuberculosis (PTB/EPTB), it allows the physician to take actions timely for antitubercular treatment …
Ayman Elbehiry, Eman Marzouk, Husam M Edrees, Riyad AlShaqi, Abousree T Ellethy, et al.
…rapeutic innovations such as shorter multidrug-resistant TB regimens and host-directed therapies. Special emphasis is placed on the translational gap-highlighting barriers to real-world implementation such as cost, infrastructure, and policy fragmentation. While innovations like …
Leeberk Raja Inbaraj, Bella Devaleenal Daniel, Chandrasekaran Padmapriyadarsini
Treatment outcomes of tuberculous meningitis (TBM), a disease with high mortality depends on early diagnosis and management. The global and regional burden of TBM and drug resistant TBM (DRTBM) are largely unknown. DRTBM is associated with poorer treatment outcomes. The wider use…
T Nkomo, Z Udwadia, D Vambe, A van Rie, S S Thi, et al.
…ew and repurposed drugs included in the all-oral shorter TB regimens recommended by WHO for the treatment of multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB) are becoming increasingly common globally. When strains ofhave resistance to one or more of these drugs (bedaquilin…
Anca Ionela Fâcă, Denisa Ioana Udeanu, Andreea Letiția Arsene, Beatrice Mahler, Doina Drăgănescu, et al.
… Nowadays, pharmacologic approaches utilise polytherapeutic regimens that, although showing increased efficacy, prominently affect the nutritional status of patients and modify multiple metabolic pathways, thus influencing both the effectiveness of therapy and the patient outcome…
Mani Sharma, Sakshi Kansal
Tuberculosis is the second most fatal infectious disease after AIDS. It is caused by the mycobacterium tuberculosis. There are numerous factors responsible for the emergence of multi-drug resistance and extensively drug resistance cases of tuberculosis, which involves high pill b…
Simon Tiberi, Temi Lampejo, Alimuddin Zumla
Rifampicin-resistant Tuberculosis (RR-TB) and Multidrug resistant Tuberculosis (MDR-TB) are a current global health threat, and are characterised by high mortality, chronic sequelae, complexity and high cost. The drug resistant form of this infectious disease was globally respons…
Mange Ram Yadav, Dushyant V. Patel, Divya Teli, Hiral Shah
Tuberculosis (TB) remains a substantial challenge for public health globally, impacting millions of individuals around the world. Despite extensive efforts to control the disease, it continues to pose a major public health challenge, involving therapeutic implications for multi-d…